Hematology-American Society of Hematology Education Program

Papers
(The H4-Index of Hematology-American Society of Hematology Education Program is 23. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)
ArticleCitations
Inherited thrombophilia and recurrent miscarriage: is there a role for anticoagulation during pregnancy?69
When should gene therapy be considered for transfusion-dependent β-thalassemia patients?69
Neurological manifestations of MGUS60
Anticoagulation at the end of life: whether, when, and how to treat41
Your chemo is no good here: management of high-risk MCL40
Hematopoietic cell transplantation for sickle cell disease: updates and future directions39
Diagnosis and therapeutic decision-making for the neutropenic patient36
On the horizon: upcoming new agents for the management of ITP35
Labor and delivery: DIC, HELLP, preeclampsia34
Mastocytosis demystified31
Bispecific antibody therapies30
Recognizing, defining, and managing CAR-T hematologic toxicities30
Inpatient recognition and management of HLH29
Has PD-1 blockade changed the standard of care for cHL?28
Individualized patient care in nodular lymphocyte-predominant Hodgkin lymphoma26
To consolidate or not to consolidate: the role of autologous stem cell transplantation in MCL25
Logistics, risks, and benefits of automated red blood cell exchange for patients with sickle cell disease25
T-cell–based therapies for treating relapsed or refractory mantle cell lymphoma25
Mutation- and MRD-informed treatment decisions for the transplant-eligible AML patient24
Double-refractory Hodgkin lymphoma: tackling relapse after brentuximab vedotin and checkpoint inhibitors24
Divergent paths: management of early relapsed follicular lymphoma23
Fitness and frailty in myeloma23
MGCS: where do we stand today?23
BV and beyond: how to incorporate novel agents into PTCL management23
How to recognize and manage COVID-19-associated coagulopathy23
0.038182973861694